← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Dana-Farber Cancer Institute, Inc.
$186,385,970
Total funding
211
Grants
Funding over time
peak $24.9M · FY2008–25$25M$18.8M$12.5M$6.3M$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
DOD$181,520,953 · 206
DOE$4,865,018 · 5
By mechanism
—$186,385,970 · 211
Investigators at Dana-Farber Cancer Institute, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Not enough data
Largest grants
RAPID BROAD-SPECTRUM ANTI-MICROBIAL IMMUNITY BY PHAGE-ANTIBODY DELIVERY AND SELECTIVE VH GERMLINE STIMULATION$9,690,066
· FY2010 · Department of Defense
CPVOD-19 DEVELOPMENT OF DF-COV FOR THE TREATMENT AND PREVENTION OF COVID-19 AND ASSOCIATED IMMUNOPATHOLOGIC RESPIRATORY COMPLICATIONS$6,881,254
· FY2021 · Defense Health Agency
RBPI21: DEVELOPMENT OF A NOVEL RADIATION MITIGATOR$5,085,102
· FY2012 · Department of Defense
INVESTIGATION OF A MULTICANCER EARLY DETECTION TEST IN A HIGH-RISK MILITARY POPULATION$4,991,950
· FY2024 · Defense Health Agency
PROSPECTIVELY RANDOMIZED, PLACEBO-CONTROLLED PHASE 3 STUDY TO DETERMINE THE EFFECT OF DENOSUMAB ON BREAST CANCER PREVENTION IN BRCA1 MUTATION CARRIERS$4,947,688
· FY2019 · Defense Health Agency
A RANDOMIZED PHASE 2 TRIAL EVALUATING THE NOVEL PI3KD INHIBITOR ROGINOLISIB WITH VENETOCLAX/RITUXIMAB FOR THE TREATMENT OF RELAPSED CLL PATIENTS$4,753,460
· FY2024 · Defense Health Agency
PRE-IND STUDIES OF FIRST-GENERATION DUAL-TARGETED, FINE-TUNED, IMMUNE-RESTORING (DFIR) CAR-T CELL THERAPY TO ACHIEVE CURES OF CLEAR CELL RENAL CELL CARCINOMA (CCRCC)$4,650,116
· FY2021 · Defense Health Agency
BIOLOGICAL AND IMMUNOLOGICAL INFECTIOUS DISEASE AGENT AND CANCER VACCINE RESEARCH$3,764,628
· FY2008 · Department of Defense
RANDOMIZED TRIAL OF ASPRIN AS ADJUVANT THERAPY FOR NODE-POSITIVE BREAST CANCER$3,287,259
· FY2015 · Department of the Army
PHARMACOLOGIC INHIBITION OF LIPOGENESIS SUPPRESSES AR AND ITS SPLICE VARIANTS TO INHIBIT PROGRESSION OF CASTRATION-RESISTANT PROSTATE CANCER$2,982,816
· FY2017 · Department of the Army
PRECISION TARGETING OF CELL CYCLE CHECKPOINTS IN TP53-MUTANT ENDOMETRIAL CANCER.$2,222,168
· FY2022 · Defense Health Agency
REVERSIBILITY AND THERAPEUTIC TARGETING OF TREATMENT- EMERGENT NEUROENDOCRINE PROSTATE CANCER$2,136,000
· FY2025 · Defense Health Agency
PROSTATE CANCER CLINICAL TRIALS CONSORTIUM: DANA-FARBER$2,136,000
· FY2022 · Defense Health Agency
REGULATION OF THE ANDROGEN RECEPTOR SPLICE VARIANT, AR-V7, IN CASTRATION-RESISTANT PROSTATE CANCER$1,820,000
· FY2017 · Department of the Army
TREATMENT OPTIONS FOR METASTATIC OSTEOSARCOMA$1,750,524
· FY2022 · Department of the Army
CDK4 AND IMMUNO-TARGETED THERAPIES IN LIVER TUMORS FORMED IN OBESITY/TYPE 2 DIABETES$1,703,227
· FY2020 · Defense Health Agency
EXPLORING THE REGULATORY LANDSCAPE OF PEDIATRIC VS ADULT GERM CELL TUMORS IN A DEVELOPMENTAL FRAMEWORK TO GAIN NEW THERAPEUTIC INSIGHTS$1,695,959
· FY2025 · Defense Health Agency
LP NETURALIZATION VIA ADMINISTRATION OF RBPI$1,660,462
· FY2008 · Defense Advanced Research Projects Agency
PROSTATE CANCER CLINICAL TRAILS CONSORTIUM: DANA-FARBER/HARVARD CANCER CENTER$1,637,500
· FY2017 · Department of the Army
TEMPORAL EVOLUTION OF N-MYC SIGNALING AND EARLY TARGETING OF THE NEUROENDOCRINE PHENOTYPE IN PROSTATE CANCER$1,606,988
· FY2017 · Defense Health Agency